Ten‐eleven translocation‐2 inactivation restrains IL‐10‐producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma
Hepatology · 2023-03 · 77 (3) · 745-759
DOI: 10.1002/hep.32442 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology, online erschienen am 17.02.2023. Verfasst von Zhou Lu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery and Transplantation , Liver Cancer Institute , Zhongshan Hospital, Fudan University , Shanghai , P.R. China. Hauptthemen laut MEDLINE: B-Lymphocytes, Regulatory, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Background and Aims: IL‐10‐producing regulatory B cells (IL‐10 + B cells), a dominant regulatory B cell (Breg) subset, foster tumor progression. However, the mechanisms underlying their generation in HCC are poorly understood. Ten‐eleven translocation‐2 (TET2), a predominant epigenetic regulatory enzyme in B cells, regulates gene expression by catalyzing demethylation of 5‐methylcytosine into 5‐hydroxymethyl cytosine (5hmC). In this study, we investigated the role of TET2 in IL‐10 + B cell generation in HCC and its prospects for clinical application. Approach and Results: TET2 activation in B cells triggered by oxidative stress from the HCC microenvironment promoted IL‐10 expression, whereas adoptive transfer of Tet2 ‐deficient B cells suppressed HCC progression. The aryl hydrocarbon receptor is required for TET2 to hydroxylate Il10 . In addition, high levels of IL‐10, TET2, and 5hmc in B cells indicate poor prognosis in patients with HCC. Moreover, we determined TET2 activity using 5hmc in B cells to evaluate the efficacy of anti‐programmed death 1 (anti‐PD‐1) therapy. Notably, TET2 inhibition in B cells facilitates antitumor immunity to improve anti‐PD‐1 therapy for HCC. Conclusions: Our findings propose a TET2‐dependent epigenetic intervention targeting IL‐10 + B cell generation during HCC progression and identify the inhibition of TET2 activity as a promising combination therapy with immune checkpoint inhibitors for HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Liver Surgery and Transplantation , Liver Cancer Institute , Zhongshan Hospital, Fudan University , Shanghai , P.R. China.
- Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education) , Zhongshan Hospital, Fudan University , Shanghai , P.R. China.
- Department of Immunology, School of Basic Medical Sciences , Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences , Fudan University , Shanghai , P.R. China.
- Shanghai Fifth People's Hospital , Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences , Fudan University , Shanghai , P.R. China.
- Department of Thoracic Surgery , Zhongshan Hospital, Fudan University , Shanghai , P.R. China.
- Huashan Hospital, Shanghai Key Laboratory of Medical Epigenetics , International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Molecular and Cell Biology Laboratory, Institute…
ORCID-Profile: Zhongchen Li, Jian Zhou
Zitieren
APA
Lu, Z., Liu, R., Wang, Y., Jiao, M., Li, Z., Wang, Z., Huang, C., Shi, G., Ke, A., Wang, L., Fu, Y., Xia, J., Wen, H., Zhou, J., Wang, X., Ye, D., Fan, J., Chu, Y., & Cai, J. (2023). Ten‐eleven translocation‐2 inactivation restrains IL‐10‐producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma. Hepatology, 77(3), 745-759. https://doi.org/10.1002/hep.32442
Vancouver
Lu Z, Liu R, Wang Y, Jiao M, Li Z, Wang Z, et al. Ten‐eleven translocation‐2 inactivation restrains IL‐10‐producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma. Hepatology. 2023;77(3):745-759. doi:10.1002/hep.32442
BibTeX
@article{Lu2023,
author = {Lu, Zhou and Liu, Ronghua and Wang, Yining and Jiao, Mengxia and Li, Zhongchen and Wang, Zhiqiang and Huang, Cheng and Shi, Guoming and Ke, Aiwu and Wang, Luman and Fu, Ying and Xia, Jie and Wen, Haoyu and Zhou, Jian and Wang, Xiaoying and Ye, Dan and Fan, Jia and Chu, Yiwei and Cai, Jiabin},
title = {Ten‐eleven translocation‐2 inactivation restrains IL‐10‐producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma},
journal = {Hepatology},
year = {2023},
volume = {77},
number = {3},
pages = {745--759},
doi = {10.1002/hep.32442}
}
EUVIMED